



Novo Nordisk is a healthcare company with an 86-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems.

In 2009, Novo Nordisk celebrates 25 years of business in Canada. Over the past 25 years, Novo Nordisk has emerged as Canada's market-leading diabetes company; the fastest growing Top 20 Canadian research based pharmaceutical company and a Top Employer in the Greater Toronto Area. Our Canadian roots run deep and can be traced through Connaught Laboratories to the original University of Toronto Labs and the first company to produce insulin for the Canadian market in the 1920s.

In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy and hormone therapy for women.

Novo Nordisk's business is driven by the triple bottom line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. With headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol "NVO."

For global information, visit novonordisk.com. For Canadian information, visit Novonordisk.ca. Novo Nordisk Canada Inc., 300-2680 Skymark Avenue, Mississauga, ON L2W 5L6. Toll-free: 1-800-465-4334.